Muscular Dystrophy, Facioscapulohumeral
15
6
7
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (15)
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Clenbuterol to Target DUX4 in FSHD
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
BetterLife FSHD: A Patient-driven Health and Research Platform
Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation
Disease Burden and Living Situation of Patients With Facioscapulohumeral Muscular Dystrophy
Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2
Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2
Digital Biotyping of FSHD Patients and Controls
Evaluation of a Textile Scapula Orthosis
Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With FSHD : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.
Physical Training Introduction in Lifestyle of Facioscapulohumeral Dystrophy Patients
Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy